EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Luteolin ameliorates neurological deficits and dopaminergic neuronal damage in MPTP-induced Parkinson’s disease mice via regulating the AKT/BNIP3 mitophagy signaling axis

Jing Ma, Yunchang Gu, Ying Wang, Fuqiang Xi, Jinqi Hao

Frontiers in Pharmacology · 2026-11-12 · 17

DOI: 10.3389/fphar.2026.1993520 ↗
AbstractBibliografische Angaben

Abstract

Background Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Luteolin, a natural dietary flavonoid monomer, exhibits neuroprotective potential; however, its molecular targets and regulatory mechanisms in PD require further exploration. Methods Network pharmacology was employed to predict potential targets of Luteolin against PD. Subsequently, a subacute MPTP-induced PD mouse model was established to evaluate the preventive and therapeutic effects of Luteolin (20, 40, and 100 mg/kg), with levodopa/benserazide serving as a symptomatic pharmacological reference. Motor performance, serum biosafety indicators (ALT, AST, BUN, Cr, CK), pro-inflammatory cytokines, oxidative stress markers, TH-positive neuronal survival, and AKT/BNIP3/LC3 pathway proteins were systematically evaluated. Results Network analysis prioritized AKT1 as a top hub target linking Luteolin to PD pathogenesis. In vivo experiments showed that MPTP intoxication led to severe motor deficits, depletion of SNpc TH-positive neurons (preserving only 43.1% compared with the Normal group, 7.50 ± 1.87 vs. 17.40 ± 2.65 cells/field, P < 0.01), elevated oxidative stress (increased ROS and MDA, decreased SOD), and reduced expression of TH, p-AKT/AKT (decreased by 67.3%), BNIP3 (decreased by 66.7%), and LC3-II/I (all P < 0.01). Luteolin treatment, particularly at medium (40 mg/kg) and high (100 mg/kg) doses, significantly attenuated oxidative stress and central inflammation (TNF-α, IL-1β, IL-6), preserved TH-positive neurons (high-dose preserving 93.1% of control levels, 16.20 ± 2.39 cells/field), and upregulated p-AKT/AKT and BNIP3 protein levels, while serum biochemical parameters of hepatic and renal functions remained within physiological baseline ranges with no significant group differences ( P > 0.05). Conclusion Luteolin confers robust neuroprotection against MPTP neurotoxicity, which is closely associated with anti-inflammatory activity, attenuation of oxidative stress, and positive modulation of AKT/BNIP3 mitophagy-related signaling proteins.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →